SPIRIT 2

SPIRIT 2 was a Phase III, multicentre, open-label, prospective randomised trial comparing imatinib 400 mg daily versus dasatinib 100 mg daily in patients with newly-diagnosed chronic phase Chronic Myeloid Leukaemia (CML).

The study opened in August 2008, closed to recruitment in 2013 and recruited 814 patients.

Patients were randomised in equal proportions to one of the following treatment groups:

a) Imatinib 400 mg daily
b) Dasatinib 100 mg daily

The primary endpoint was to compare Event Free Survival (EFS) between the two arms at 5 years.

Last patient last visit was in March 2018.

The team are currently working towards closing all sites down and preparing the final report & publications.